# Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Study · id `cardio:ct-nct01356849` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01356849](<https://clinicaltrials.gov/study/NCT01356849>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01356849

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

## Technical summary

Registry record NCT01356849. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 149 participants (enrolled count; ClinicalTrials.gov record NCT01356849, source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)
- Start date: 2011-04 (registry gives no type) (ClinicalTrials.gov record NCT01356849, source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)
- Primary completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01356849, source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)
- Completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01356849, source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)
- Countries: United States; Canada; Puerto Rico; Taiwan (ClinicalTrials.gov record NCT01356849, source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01356849-2013-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
- Acronym: RADAR
- Condition: Chronic Kidney Disease
- Condition: Diabetic Nephropathy
- Intervention (Drug): Atrasentan
- Intervention (Drug): Placebo
- Lead sponsor: AbbVie (prior sponsor, Abbott)
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: f45da3301c5611ef0f98b3276f15288aafe7337127a689be08e657847d248eba
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
